louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06120738: The Effect Of Smartphone Addiction On Trunk Muscles Performance In Adolescents
Official title: The Effect Of Smartphone Addiction On Trunk Muscles Performance In Adolescents
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Smartphone Addiction
Muscle Weakness Condition
Adolescents
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2023-11-07
Enrollment: 66
Sex: ALL
Minimum age (years): 14
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Sixty - six normal healthy adolescent from both genders will be recruited for the study from high school students and first year university students, they will be divided according to their smart phone addiction scale short version (SAS-SV) scores into two groups:

Group (A): smartphone addicts (consists of 33 participants) Group (B): smartphone non- addicts (consists of 33 participants)

Brief summary: Statement of the problem:

Does overuse of the smartphones affect trunk muscles performance in normal adolescents it will be assumed that There will be no affection of smartphone addiction on trunk muscles performance in normal adolescents

Detailed description: * Subjects:

  - Sixty - six normal healthy adolescent from both genders will be recruited for the study from high school students and first year university students, they will be divided according to their smart phone addiction scale short version (SAS-SV) scores into two groups: Group (A): smartphone addicts (consists of 33 participants) Group (B): smartphone non- addicts (consists of 33 participants)
* Inclusion criteria

  * Age ranges from 14 to 18 years
  * Have Body Mass Index (BMI) = 5th percentile to less than the 85th percentile 2. Exclusion criteria

Subjects will be excluded from the study if he/she has:

* visual or hearing defects
* overweight or obese
* neurological disorder
* marked musculoskeletal problem

Eligibility criteria: Inclusion Criteria:

* Age ranges from 14 to 18 years
* Have Body Mass Index (BMI) = 5th percentile to less than the 85th percentile

Exclusion Criteria:

* Subjects will be excluded from the study if he/she has:
* visual or hearing defects
* overweight or obese
* neurological disorder
* marked musculoskeletal problem

Primary outcomes:
measure: evaluation of the trunk muscles performance
timeFrame: baseline only
Secondary outcomes:
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: the Governement'S Secondary School and Universities
city: Tanta
country: Egypt
facility: the Governement'S Secondary Schools and Universities
Study officials:
affiliation: Cairo University
name: Aya Elkomy, PHD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05873738: Smoking Cessation in a Cohort HIV+ Rio de Janeiro, Brazil.
Official title: Smoking Cessation is Associated With Short-term Improvement of Vascular Health in a Cohort of People Living With HIV in Rio de Janeiro, Brazil.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Smoking Cessation
Brachial Flow Mediated Dilatation
Nicotine Replacement Therapy
Lead sponsor: Instituto Fernandes Figueira
Sponsor class: OTHER_GOV
First posted: 2023-05-24
Enrollment: 115
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adults HIV positive who had attitudes toward quitting smoking and had no contraindications to study pharmacotherapy

Brief summary: The study was carried out within a large, urban prospective cohort of PLHIV at the Instituto Nacional de Infectologia Evandro Chagas (INI). Located in Rio de Janeiro, Brazil, INI is a national public referral center for PLWHA receiving primary care since 1998. From December 2019, adults who had attitudes toward quitting smoking and had no contraindications to study pharmacotherapy were enrolled by active site searching


Eligibility criteria: Inclusion Criteria:

* individuals were deemed as regular smokers, defined as the consumption of one or more pack (20 cigarettes) per week in the past 6 months, and expired carbon monoxide (CO) measurement \> 10 ppm at the screening visit.

Exclusion Criteria:

* previous use of transdermal nicotine patches or bupropion in the last 6 months; (ii) contraindication to nicotine patches; (iii). Pregnancy; (iv) breastfeeding

Primary outcomes:
measure: FMD
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Rio de Janeiro
country: Brazil
facility: Instituto Nacional de Infectologia Evandro Chagas
Study officials:
References:
Clinical trial NCT01027338: Tai Chi Exercise in Patients With COPD
Official title: Tai Chi Exercise in Patients With Chronic Obstructive Pulmonary Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: COPD
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH)
Sponsor class: NIH
First posted: 2009-12-07
Sex: ALL
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no

Brief summary: This is a pilot randomized controlled trial of feasibililty and prelimnary effects of a 12 week tai chi intervention vs. usual care in patients with chronic obstructive pulmonary disease


Eligibility criteria: Inclusion Criteria:

* physician diagnosis of COPD
* FEV1\<65% of predicted and FEV1/FVC\<70% of predicted
* ≥45 years old

Exclusion Criteria:

* COPD exacerbation requiring ER visit or hospitalization within past month
* planned major pulmonary intervention in coming 3 months
* severe peripheral vascular disease/claudication or other physical condition precluding walk test
* inability to perform bicycle ergometry
* severe cognitive dysfunction (MMSE ≤ 24)
* inability to speak English
* current participation in a pulmonary rehabilitation or regular practice of tai chi

Primary outcomes:
measure: study feasibility
Secondary outcomes:
measure: quality of life
measure: exercise capacity
Other outcomes:
Locations:
city: Boston
country: United States
facility: Beth Israel Deaconess Medical Center
state: Massachusetts
Study officials:
affiliation: Beth Israel Deaconess Medical Center
name: Gloria Y Yeh, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00568438: Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival & Frozen Tissue Sample
Official title: Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival and Frozen Human Tissue Samples
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Cancer
Stomach Neoplasms
Salivary Gland Neoplasms
Thyroid Cancer
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2007-12-06
Enrollment: 169
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Cases will be identified from clinic patient medical records and linked to pathology reports. The surgical pathology record number will thus be obtained and used to retrieve the archival blocks and slides. In addition, all these participants will be clinical patients of the Protocol Director, thus the Physician will always be familiar with the participants.

Brief summary: The goal of this study is to study NIS expression in benign and malignant breast and thyroid samples using archival formalin-fixed paraffin-embedded tissue sections.

Detailed description: The objective of the study is to further understanding of proteins that occur in both normal cells and tumor cells and to learn more about certain diseases and potential alternative treatments for these diseases.

Eligibility criteria: Inclusion Criteria:

1. Patient must be over the age of 18.
2. Patients must have benign and malignant breast and thyroid cancer.
3. Patient mus sign consent form.

Exclusion Criteria:

1. No children will be allowed.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University School of Medicine
state: California
Study officials:
affiliation: Stanford University
name: Irene L Wapnir, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05560438: Technology Assisted Rehabilitation for Upper Limb Function in Myotonic Dystrophy Type 1
Official title: Technology Assisted Rehabilitation for Upper Limb Function in Myotonic Dystrophy Type 1
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Myotonic Dystrophy Type 1 (DM1)
Lead sponsor: University of Oslo
Sponsor class: OTHER
Collaborators: name: Oslo University Hospital
name: Vikersund Rehabilitation Center
First posted: 2022-09-29
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Single subject experimental design (SSED) study
Primary purpose: TREATMENT

Brief summary: Myotonic Dystrophy type 1 (DM1) is a genetic multisystem disease causing muscle weakness and myotonia. As a result, upper limb function might become impaired. There are little research regarding rehabilitation and exercise for upper limb function in DM1. It is known from research on lower limb function in DM1 and other muscular dystrophies, that there are possibilities to improve function also in these deteriorating diseases. In this single subject experimental design study, 6-10 adults with DM1, who are at an inpatient rehabilitation center, will get intensive, but personally adapted senso- and robot assisted rehabilitation for arm- and hand function with Tyromotion Amadeo and Armeo Senso. These devices have previously been used in rehabilitation research for other neurological conditions. The participants will be followed up, and evaluated at a weekly basis, using video consultations. Fine motor skill dexterity test (9HPT) and the Nut and Bolt test will be used, and active range of motion (ROM) and muscle strenght and movement of upper limb will be measured. Furthermore, patient reported outcome measures (PROMS) on hand impairment and myotonia will be used, all with purpose to evaluate upper limb function.


Eligibility criteria: Inclusion Criteria:

* Granted rehabilitation at Vikersund Rehabilitation center Genetical confirmed myotonic dystrophy diagnosis MIRS score between 2-5

Exclusion Criteria:

* MIRS score on 1 Reduced Cognitive function and unable to participate in technological rehabilitation and digital evaluation

Primary outcomes:
measure: Fine motor skill dexterity test, 9 hole peg test (9HPT)
timeFrame: 1-3 minutes
Secondary outcomes:
measure: Range of motion (ROM)
timeFrame: 5-10 minutes
measure: Nut and Bolt test
timeFrame: 5 minutes
measure: Hand strength
timeFrame: 5 minutes
measure: Pinch Gauge
timeFrame: 5 minutes
Other outcomes:
measure: Abilhand
timeFrame: 5 minutes
measure: Myotonia behavior scale
timeFrame: 1-5 minutes
Locations:
city: Vikersund
country: Norway
facility: Vikersund Rehabilitation Center
state: Viken
Study officials:
affiliation: University of Oslo
name: Hilde Stendal Robinson, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00489138: Prospective, Open-label Study of Pharmacokinetics of Ertapenem in the Muscle Using Microdialysis in Mechanically Ventilated Intensive Care Unit Patients, Treated or Not by Norepinephrine
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: To Assess the Tissular and Plasma Kinetics of Ertapenem
Lead sponsor: Assistance Publique Hopitaux De Marseille
Sponsor class: OTHER
First posted: 2007-06-21
Enrollment: 9
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Goal of study:

To assess the tissular and plasma kinetics of ertapenem;

To determine the optimal dosages in the patients according to norepinephrine administration:

* to assess muscular diffusion of free form of ertapenem after administration to mechanically ventilated patients requiring such a treatment. The patients are included in the groups "with norepinephrine" or "without norepinephrine" according to their hemodynamic status.
* to assess the plasma pharmacokinetics of ertapenem in mechanically ventilated patients treated or not by norepinephrine.

Open-label, prospective study performed in a single ICU (16 beds) of a tertiary hospital (700 beds).


Eligibility criteria: Inclusion Criteria:

* 18 years and more
* negative pregnancy test
* HIV/HBV, HCV negative tests
* Mechanical ventilation with pneumonia or intraabdominal infection requiring ertapenem

Exclusion Criteria:

* refractory septic shock requiring use of additional catecholamines
* patients with positives tests for HIV, HBV, HCV
* pregnant females
* allergic insufficiency
* hemodiafiltration
* contraindication to microdialysis catheter set-up
* severe arteritis of lower extremities
* treatment with vasodilatators
* prior history of aorto-iliac shunt
* involvement in a clinical trial in the last three months
* exclusion from national records
* non affiliated to "securité sociale"

Primary outcomes:
measure: assess the tissular and plasma kinetics of ertapenem
timeFrame: 24 months
Secondary outcomes:
Other outcomes:
Locations:
city: Marseille
country: France
facility: Département d'Anesthésie-Réanimation - CHU NORD
Study officials:
affiliation: Assistance Publique Hôpitaux de Marseille
name: Ioanna BOYADJIEV, PH
role: PRINCIPAL_INVESTIGATOR
References:
citation: Boyadjiev I, Boulamery A, Simon N, Martin C, Bruguerolle B, Leone M. Penetration of ertapenem into muscle measured by in vivo microdialysis in mechanically ventilated patients. Antimicrob Agents Chemother. 2011 Jul;55(7):3573-5. doi: 10.1128/AAC.00180-11. Epub 2011 May 16.
Clinical trial NCT06535438: The Role of Noncontrast Computed Tomography Markers in Predicting the Clinical Outcome of Cerebral Hemorrhage
Official title: The Role of Noncontrast Computed Tomography Markers in Predicting the Clinical Outcome of Cerebral Hemorrhage
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Intracerebral Hemorrhage
Keywords: ICH
Lead sponsor: Huashan Hospital
Sponsor class: OTHER
First posted: 2024-08-02
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with cerebral hemorrhage who met the criteria and were admitted continuously within the time period

Brief summary: The goal of this observational study is to To investigate the ability of Noncontrast Computed Tomography to predict clinical prognosis in Intracerebral Hemorrhage.

The main question it aims to answer is:How to judge the prognosis of patients with cerebral hemorrhage by CT image reading at admission.


Eligibility criteria: Inclusion Criteria:

1. Age≥18 years
2. had completed a CT examination within 24 h of disease onset;
3. had a hemorrhage that was located in the brain parenchyma, including the basal ganglia, thalamus,brain lobes, brainstem, and cerebellum.

Exclusion Criteria:

1. had secondary ICH caused by brain trauma,cerebrovascular malformations, aneurysms, and tumors;
2. had ischemic cerebral infarction hemorrhagic transformation;
3. had undergone surgical treatment (e.g.hematoma removal or puncture drainage) before the CT examination;
4. had images of poor quality that could notbe accurately evaluated;
5. had a hematoma withborders that could not be delineated, thus precluding delineation of the region of interest (ROI).

Primary outcomes:
measure: The prognosis of cerebral hemorrhage at 90 days
timeFrame: 90 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05751538: Artificial Intelligence in Computed Tomography for Quantifying Lung Changes of Bronchiectasis Patients
Official title: Artificial Intelligence Based on Machine Learning in Computed Tomography for Quantifying Lung Changes of Bronchiectasis Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Bronchiectasis
Keywords: Bronchiectasis
Machine Learning
Artificial Intelligence
Lead sponsor: Ruijin Hospital
Sponsor class: OTHER
First posted: 2023-03-02
Enrollment: 730
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with bronchiectasis and clinical examination, pulmonary function test, and CT data

Brief summary: Bronchiectasis is a chronic respiratory disease characterized by permanent bronchiectasis.The incidence and prevalence of bronchiectasis have assumed continuously grows in global. Chest computed tomography (CT) remains the imaging standard for demonstrating cystic fibrosis (CF) airway structural disease in vivo. However, visual scoring systems as an outcome measure are time consuming, require training and lack high reproducibility. Our objective was to validate a fully automated artificial intelligence (AI)-driven scoring system of CF lung disease severity.


Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with bronchiectasis (according to the Chinese consensus, patient's previous chest CT examination must show bronchiectasis)

Exclusion Criteria:

* Patients with CT data and medical records missing

Primary outcomes:
measure: Correlations of the artificial intelligence-driven scores with manual scores
timeFrame: From date of inclusion until the date of final quantification, assessed up to 12 months
Secondary outcomes:
measure: Correlation of the artificial intelligence-driven scores with pulmonary function test
timeFrame: From date of inclusion until the date of final quantification, assessed up to 12 months
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Ruijin Hospital, Medical School of Shanghai Jiaotong University
state: Shanghai
Study officials:
References:
Clinical trial NCT00584038: Improving Adolescent Adherence to Hormonal Contraception
Official title: Improving Adolescent Adherence to Hormonal Contraception
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Contraception
Keywords: contraceptive compliance
educational intervention
oral contraception
Lead sponsor: The University of Texas Medical Branch, Galveston
Sponsor class: OTHER
First posted: 2008-01-02
Enrollment: 1155
Sex: FEMALE
Minimum age (years): 16
Maximum age (years): 24
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determine whether contraceptive compliance by young women can be improved through expanded counseling by a health educator at the initial clinic visit as compared with standard care.


Eligibility criteria: Inclusion criteria:

* Sexually active females 16 to 24 years of age who present to a University of Texas Medical Branch (UTMB) clinic and request to initiate oral contraception for birth control.

Exclusion criteria:

* Women who are currently pregnant or breastfeeding.
* Women who wish to become pregnant within the next 12 months.
* Women who have a medical contraindication to use of estrogen (e.g., thromboembolic disease, acute liver disease, breast cancer, genital cancer, or undiagnosed genital bleeding).
* Women wishing to initiate use of a contraceptive method that is not oral, such as transdermal (the patch) or injectable (DMPA) methods, or the vaginal ring.
* Current and previous users of oral contraceptives.

Primary outcomes:
measure: Measurement of contraceptive adherence
timeFrame: 12 months
measure: Measurement of dual method use
timeFrame: 12 months
measure: Measurement of pregnancy rates and sexually transmitted diseases (STDs)
timeFrame: 12 months
Secondary outcomes:
measure: Measurement of contraceptive side effects
timeFrame: 12 months
measure: Measurement of satisfaction with method
timeFrame: 12 months
measure: Measurement of sexual activity
timeFrame: 12 months
Other outcomes:
Locations:
city: Galveston
country: United States
facility: The University of Texas Medical Branch
state: Texas
Study officials:
affiliation: The University of Texas Medical Branch, Galveston
name: Abbey B. Berenson, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Berenson AB, Rahman M. A randomized controlled study of two educational interventions on adherence with oral contraceptives and condoms. Contraception. 2012 Dec;86(6):716-24. doi: 10.1016/j.contraception.2012.06.007. Epub 2012 Jul 25.
Clinical trial NCT01157338: Clinical Significance of Retinal Emboli During Diagnostic and Therapeutic Cardiac Catheterization
Official title: Clinical Significance of Retinal Emboli During Diagnostic and Therapeutic Cardiac Catheterization
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cardiac Catheterization
Retina
Embolism
Keywords: Catheter
coronary artery disease
embolus
stroke
retinal emboli
Lead sponsor: Shiraz University of Medical Sciences
Sponsor class: OTHER
First posted: 2010-07-07
Enrollment: 300
Sex: ALL
Minimum age (years): 52
Maximum age (years): 68
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Retinal emboli is a common phenomenon in cardiac catheterization. In this study the investigators evaluate the incidence of retinal emboli post diagnostic and therapeutic cardiac catheterization over 300 patients. The incidence was 6.3% and had no clinical sequel on visual acuity and visual field.

Detailed description: Background and Purpose Cardiac catheterization may cause retinal embolization, a risk factor for cerebrovascular emboli and stroke. We describe the incidence of clinically silent and apparent retinal emboli following diagnostic and interventional coronary catheterization and associated risk factors.

Methods Three hundred selected patients attending a tertiary referral center for diagnostic and therapeutic cardiac catheterization were studied. Direct retinal examination and examination of the visual field and acuity were done before and after catheterization by a retinal specialist.

Eligibility criteria: Inclusion Criteria:

* every patient with diagnostic and therapeutic cardiac catheterization

Exclusion Criteria:

* patient refusal to follow up ophthalmology
* abscence of coronary disease in angiogram
* abnormal retinal angiogram prior to study

Primary outcomes:
measure: retinal emboli
Secondary outcomes:
measure: visual field
measure: visual acuity
Other outcomes:
Locations:
city: Shiraz
country: Iran, Islamic Republic of
facility: shiraz University of medical sciences
state: Fars
Study officials:
References:
citation: Kojuri J, Mehdizadeh M, Rostami H, Shahidian D. Clinical significance of retinal emboli during diagnostic and therapeutic cardiac catheterization in patients with coronary artery disease. BMC Cardiovasc Disord. 2011 Jan 21;11:5. doi: 10.1186/1471-2261-11-5.